| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | AERIE PHARMACEUTICALS INC | 1,672,714 | 63,128,000 | 30.14% | ||
| 2 | AIMMUNE THERAPEUTICS INC COM | 3,967,900 | 59,519,000 | 28.42% | ||
| 3 | ALDER BIOPHARMACEUTICALS INC | 802,724 | 26,305,000 | 12.56% | ||
| 4 | UNIVERSAL AMERN CORP NEW | 2,820,791 | 21,579,000 | 10.30% | ||
| 5 | EPIZYME INC COM | 1,543,118 | 15,184,000 | 7.25% | ||
| 6 | NANOSTRING TECHNOLOGIES INC | 752,857 | 15,042,000 | 7.18% | ||
| 7 | NEXVET BIOPHARMA PUB LTD CO | 900,155 | 3,736,000 | 1.78% | ||
| 8 | ZAFGEN INC COM | 760,046 | 2,516,000 | 1.20% | ||
| 9 | Orexigen Therapeutics, Inc. | 542,755 | 1,802,000 | 0.86% | ||
| 10 | BioDelivery Sciences International Inc | 225,281 | 608,000 | 0.29% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001144204-16-133782, filed 2016.11.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
